CXCR-4 overexpression is correlated with poor prognosis in a broad spectrum of cancers, including colorectal cancer [10], melanoma [11,12], breast cancer [13], and prostate cancer [14]. This evidence concerns the gene CXCR4 and prostate carcinoma.